CEOCFO Magazine Interviewed Aclipse Therapeutics CEO Raymond Houck

online καζίνο Λουτράκι: Οδηγός επαλήθευσης λογαριασμού

Τι είναι το online καζίνο Λουτράκι; Πώς να ξεκινήσεις: Εγγραφή και Επαλήθευση Μπόνους & Προσφορές στο Online Καζίνο Λουτράκι Μεθόδοι

August 8, 2026

Aclipse Therapeutics to Collaborate with Mayo Clinic on Phase 2 Clinical Development of M107 for the Treatment of Gastroparesis

KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that it has entered into a clinical

November 19, 2025

Aclipse Therapeutics Selected to Present M102 ALS Clinical Development Program at Prestigious ALS and Motor Neurone Disease Symposia

KING OF PRUSSIA, Penn.–(BUSINESS WIRE)–Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that its M102 drug development program has

November 10, 2024

Aclipse Therapeutics Expands Drug Development Pipeline

Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to

September 14, 2023

March 11, 2021

CEOCFO Magazine has interviewed Aclipse Therapeutics CEO Raymond Houck. Mr. Houck has introduced the background of the company and our lead drug product M102. He has also described the target pathomechanisms of M102 and its precision medicine approach to ALS and CNS diseases.

Learn More